Carregant...
Myelofibrosis in 2019: moving beyond JAK2 inhibition
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation to acute myeloid leukemia. The discovery of mutations in JAK2, CALR, and MPL have uncovered activated JAK-STAT signaling as...
Guardat en:
| Publicat a: | Blood Cancer J |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6739355/ https://ncbi.nlm.nih.gov/pubmed/31511492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0236-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|